Chapter 46, Problem 7NERQ

Summary Introduction

To define:

The nurse prepares the dose of bevacizumab for the patient’s intravenous infusion. The pharmacy has prepared the bevacizumab with the concentration of 70 mg/100 mL and the drug, bevacizumab is to infuse over 90 minutes. Therefore, what rate of this dose will be set by the nurse for the intravenous infusion pump?

Concept introduction:

Bevacizumab (Avastin) is a cell-cycle nonspecific antineoplastic drug (an angiogenesis inhibitor) used to treat colon cancer, non-small cell lung cancer, rectal cancer, and malignant glioblastoma. It prevents or suppresses the growth of cancer progression by inhibiting the formation of the blood vessels, which is essential to provide oxygen and nutrient to cancer cell growth. The bevacizumab anticancer drug can cause various adverse effects, including the cardiovascular problem, renal dysfunction, and gastrointestinal problems.